Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163 ETRAL trial)

C. Soulie, L. Assoumou, B. Abdi, S. Sayon, T. Nguyen, MA Valantin, L. Benigue, V. Ferre, C. Alloui, B. Montes, V. Avettand-Fenoel, C. Delaugerre, D. Descamps, E. Martinez, J. Reynes, G. Peytavin, D. Costagliola, C. Katlama, V. Calvez, and AG Marcelin on behalf of the ANRS-163 ETRAL study group. Journal of Antimicrobial Chemotherapy, 2020 Jul 1;75(7):1943-1949.doi: 10.1093/jac/dkaa090. This email address is being protected from spambots. You need JavaScript enabled to view it.

Citation: "... In this study, 19 patients experienced VR, with 2 patients having virological failure (VF; two consecutive VLs >50 copies/mL). For the first patient with VF, UDS detected minority resistant variants only in RT (K103N, 9.6%; Y181C, 4.9%) at baseline. ... Illumina sequencing technology (MiSeq) was used to study HIV DNA and RNA RT and integrase mutations. RT and integrase mutations were analysed with SmartGene® according to the latest ANRS mutation list (cutoff 1%) and by Genious (v10.3.2; ..."